Form D · Biotechnology
Platform Therapeutics, Inc.
Andover, MA · CIK 0002152141
Offering snapshot reported Aug 27, 2026 · SEC filing
- Reported sold
- $1.75M Offering amount: $4M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 12, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 27, 2026 | Initial | $1,750,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-595631
BREIBRE
Source: Form D, filed Aug 27, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lakhmir Chawla | Director |
| James Wilkie | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
300 Brickstone Square, Ste 201
Andover, MA, 01810
Phone: 339-224-0265
Andover, MA, 01810
Phone: 339-224-0265